Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BAX | Q07812 | 2/20 | 0.58 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.49 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.47 |
| ▸ | MAPT | P10636 | 6/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | HTR7 | P34969 | 2/20 | 0.42 |
| ▸ | PTPRC | P08575 | 2/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | S100A4 | P26447 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14721556 | 0.85 | BAX (0.61) | BAXALDH1A1MAPTSMN1; SMN2KMT2A | |
| SCHEMBL14721458 | 0.85 | BAX (0.65) | BAXALDH1A1MAPTSMN1; SMN2KMT2A | |
| SCHEMBL15840937 | 0.85 | BAX (0.61) | BAXALDH1A1MAPTSMN1; SMN2KMT2A | |
| SCHEMBL14721248 | 0.85 | BAX (0.65) | BAXALDH1A1MAPTSMN1; SMN2KMT2A | |
| SCHEMBL14721558 | 0.85 | BAX (0.61) | BAXALDH1A1MAPTSMN1; SMN2KMT2A | |
| SCHEMBL15837194 | 0.85 | BAX (0.61) | BAXALDH1A1MAPTSMN1; SMN2KMT2A | |
| SCHEMBL15840905 | 0.85 | BAX (0.58) | BAXALDH1A1MAPTSMN1; SMN2KMT2A | |
| SCHEMBL15837173 | 0.84 | BAX (0.60) | BAXALDH1A1MAPTSMN1; SMN2KMT2A | |
| SCHEMBL15837175 | 0.83 | BAX (0.59) | BAXALDH1A1MAPTSMN1; SMN2KMT2A | |
| SCHEMBL14721267 | 0.83 | BAX (0.67) | BAXALDH1A1MAPTSMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9402850-B2 | BAX agonist, compositions, and methods related thereto | EMORY UNIVERSITY (US) | 2016-08-02 | — | — | US | disclosed |
| US-9402850-B2 | BAX agonist, compositions, and methods related thereto | EMORY UNIVERSITY (US) | 2016-08-02 | — | — | US | disclosed |
| US-20150250793-A1 | BAX AGONIST, COMPOSITIONS, AND METHODS RELATED THERETO | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-09-10 | — | — | US | disclosed |
| US-20150250793-A1 | BAX AGONIST, COMPOSITIONS, AND METHODS RELATED THERETO | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-09-10 | — | — | US | disclosed |
| US-9040567-B2 | BAX agonist, compositions, and methods related thereto | EMORY UNIVERSITY (US) | 2015-05-26 | — | — | US | disclosed |
| US-9040567-B2 | BAX agonist, compositions, and methods related thereto | EMORY UNIVERSITY (US) | 2015-05-26 | — | — | US | disclosed |
| US-20140178374-A1 | BAX AGONIST, COMPOSITIONS, AND METHODS RELATED THERETO | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-06-26 | — | — | US | disclosed |
| US-20140178374-A1 | BAX AGONIST, COMPOSITIONS, AND METHODS RELATED THERETO | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140178374-A1 | BAX AGONIST, COMPOSITIONS, AND METHODS RELATED THERETO | BAX, BID, BAD | BAX 1/4885CHRNB2 492/4885CHRNA4 856/4885 |
| US-20150250793-A1 | BAX AGONIST, COMPOSITIONS, AND METHODS RELATED THERETO | BAX, ANXA1, BAD | BAX 1/4885CHRNB2 146/4885CHRNA4 606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.